DR. MAHER ALBITAR
Medical Laboratory at Ortega Hwy, San Juan Capistrano, CA
License number
California C51297
Category
Medical Laboratory
Type
Clinical Medical Laboratory
Address
Address
2
33608 Ortega Hwy, San Juan Capistrano, CA 92675
3 River Rock Dr, Trabuco Canyon, CA 92679
3 River Rock Dr, Trabuco Canyon, CA 92679
Phone
(949) 728-4784
Professional information
Maher Albitar, San Juan Capistrano CA
Specialties:
Pathologist
Address:
33608 Ortega Hwy, San Juan Capistrano, CA 92675
Education:
University of Damascus, Faculty of Medicine - Doctor of Medicine
Hospital of the University of Pennsylvania - Fellowship - Genetics
Hospital of the University of Pennsylvania - Fellowship - Hematology (Pathology)
Rhode Island Hospital - Residency - Pathology
Hospital of the University of Pennsylvania - Fellowship - Genetics
Hospital of the University of Pennsylvania - Fellowship - Hematology (Pathology)
Rhode Island Hospital - Residency - Pathology
Board certifications:
American Board of Pathology Certification in Clinical Pathology (Pathology)
Ubiquitin Proteasome System Profiling And The Use Thereof In Clinical Applications For Cancer Diagnosis
US Patent:
2011005, Mar 3, 2011
Filed:
Aug 23, 2010
Appl. No.:
12/861683
Inventors:
Maher Albitar - Coto De Caza CA, US
Wanlong Ma - Aliso Viejo CA, US
Ke Zhang - Thousand Oaks CA, US
Xi Zhang - Aliso Viejo CA, US
Xiuqiang Wang - Irvine CA, US
Kevin Qu - Irvine CA, US
Anthony Sferruzza - San Clemente CA, US
Wanlong Ma - Aliso Viejo CA, US
Ke Zhang - Thousand Oaks CA, US
Xi Zhang - Aliso Viejo CA, US
Xiuqiang Wang - Irvine CA, US
Kevin Qu - Irvine CA, US
Anthony Sferruzza - San Clemente CA, US
International Classification:
C12Q 1/37
US Classification:
435 24
Abstract:
Provided herein are methods for the diagnosis, prognosis, or management of neoplastic diseases, i.e. cancer, and other diseases using profiles of the ubiquitin-protcasome system determined from acellular body fluids or cell-containing samples. Further provided are methods of predicting response to therapy in certain populations of cancer patients.
Wt1 Mutations For Prognosis Of Myeloproliferative Disorders
US Patent:
2013028, Oct 31, 2013
Filed:
Oct 29, 2010
Appl. No.:
13/509271
Inventors:
Maher Albitar - Coto De Caza CA, US
Wanlong Ma - Aliso Viejo CA, US
Wanlong Ma - Aliso Viejo CA, US
International Classification:
C12Q 1/68
US Classification:
435 611
Abstract:
The invention provides methods for determining the prognosis of a patient diagnosed with a leukemia, including B-cell chronic lymphocytic leukemia, by measuring mutations of the WT1 gene in a biological sample. The invention also relates to the diagnosis of leukemia, including B-cell chronic lymphocytic leukemia.
Methods For Detecting Gene Dysregulation By Intragenic Differential Expression
US Patent:
8426133, Apr 23, 2013
Filed:
May 24, 2010
Appl. No.:
12/786266
Inventors:
Heather R. Sanders - Winchester CA, US
Maher Albitar - Coto De Caza CA, US
Aurelia Meloni-Ehrig - Gainesville VA, US
Maher Albitar - Coto De Caza CA, US
Aurelia Meloni-Ehrig - Gainesville VA, US
Assignee:
Quest Diagnostics Investments Incorporated - Wilmington DE
International Classification:
C12Q 1/68, C12P 19/34
US Classification:
435 612, 435 912
Abstract:
Described herein are methods, compositions and kits directed to the detection of gene dysregulations such as those arising from gene fusions and/or chromosomal abnormalities, e. g. translocations, insertions, inversions and deletions. Samples containing dysregulated gene(s) of interest may show independent expression patterns for the 5′ and 3′ regions of the gene. The methods, compositions and kits are useful for detecting mutations that cause the differential expression of a 5′ portion of a target gene relative to the 3′ region of the target gene.
Proteasomal Peptidase Activity And The Use Thereof In Clinical Applications
US Patent:
2008011, May 22, 2008
Filed:
Mar 13, 2007
Appl. No.:
11/685651
Inventors:
Maher Albitar - Coto De Caza CA, US
International Classification:
C12Q 1/37
US Classification:
435 23, 435 24
Abstract:
Provided herein are methods for the diagnosis, prognosis, or management of hematological disorders and other diseases using the proteasome activity levels determined in acellular body fluids or cell-containing samples. Also provided are methods of monitoring treatment with proteasome inhibitors through assaying proteasome activity in acellular body fluids. Further provided are methods of predicting response to therapy in certain populations of leukemia patients.
Ubiquitin Proteasome System Profiling And The Use Thereof In Clinical Applications For Proliferative Hematological Disorders
US Patent:
2011005, Mar 3, 2011
Filed:
Aug 25, 2009
Appl. No.:
12/547455
Inventors:
Maher Albitar - Coto De Caza CA, US
Wanlong Ma - Aliso Viejo CA, US
Ke Zhang - Thousand Oaks CA, US
Wanlong Ma - Aliso Viejo CA, US
Ke Zhang - Thousand Oaks CA, US
International Classification:
C12Q 1/37, C12Q 1/02
US Classification:
435 24, 435 29
Abstract:
Provided herein are methods for the diagnosis, prognosis, or management of proliferative hematological disorders and other diseases using profiles of the ubiquitin-proteasome system determined from acellular body fluids or cell-containing samples. Further provided are methods of predicting response to therapy in certain populations of leukemia patients.
Mpl Mutations In Jak2 V617F Negative Patients With Myeloproliferative Disease
US Patent:
2013005, Feb 28, 2013
Filed:
Dec 2, 2010
Appl. No.:
13/511845
Inventors:
Wanlong Ma - Aliso Viejo CA, US
Maher Albitar - Coto De Caza CA, US
Maher Albitar - Coto De Caza CA, US
Assignee:
QUEST DIAGNOSTICS INVESTMENTS INCORPORATED - Wilmington DE
International Classification:
C12Q 1/68, G01N 33/574, C40B 30/04
US Classification:
506 9, 435 611, 436501, 435 792, 436 89, 435 74
Abstract:
The invention provides compositions and methods for diagnosing a patient as having a myeloproliferative disease by identifying mutations in the MPL gene or gene products.
Methods For Detecting Tcr-Gamma Gene Rearrangement
US Patent:
8367330, Feb 5, 2013
Filed:
Jun 24, 2009
Appl. No.:
12/491170
Inventors:
Maher Albitar - Coto De Caza CA, US
Assignee:
Quest Diagnostics Investments Incorporated - Wilmington DE
International Classification:
C12Q 1/68
US Classification:
435 61
Abstract:
The invention provides methods for detection of TCR-γ nucleic acid in acellular body fluid. The methods can be used to detect the TCR-γ gene rearrangement in acellular body fluid. The detection of TCR-γ gene rearrangement is useful in determination of clonality of T-cell population. The invention is useful in the diagnosis of lymphoproliferative disorder.
Methods For Detecting Mutations In Jak2 Nucleic Acid
US Patent:
2007024, Oct 25, 2007
Filed:
Apr 20, 2006
Appl. No.:
11/408241
Inventors:
Maher Albitar - Coto De Caza CA, US
Wanglong Ma - Aliso Viejo CA, US
Wanglong Ma - Aliso Viejo CA, US
International Classification:
C12Q 1/68
US Classification:
435006000
Abstract:
The present invention relates to methods for detecting JAK2 nucleic acid in acellular bodily fluid samples from patients with neoplastic disease and determining if the nucleic acid contains one or more mutations or one mutation and one deletion. The methods are useful for diagnosing patients that have cells with mutations in the JAK2 gene that effect kinase activity. The detection of such mutations can be used to determine treatment for patients or stratifying patients for therapy and management.
Ubiquitin Proteasome System Profiling And The Use Thereof In Clinical Applications For Cancer Diagnosis
US Patent:
2011005, Mar 3, 2011
Filed:
Aug 25, 2009
Appl. No.:
12/547460
Inventors:
Maher Albitar - Coto De Caza CA, US
Wanlong Ma - Aliso Viejo CA, US
Ke Zhang - Thousand Oaks CA, US
Xi Zhang - Aliso Viejo CA, US
Xiuqiang Wang - Irvine CA, US
Kevin Qu - Irvine CA, US
Anthony Sferruzza - San Clemente CA, US
Wanlong Ma - Aliso Viejo CA, US
Ke Zhang - Thousand Oaks CA, US
Xi Zhang - Aliso Viejo CA, US
Xiuqiang Wang - Irvine CA, US
Kevin Qu - Irvine CA, US
Anthony Sferruzza - San Clemente CA, US
International Classification:
C12Q 1/37
US Classification:
435 23
Abstract:
Provided herein are methods for the diagnosis, prognosis, or management of neoplastic diseases, i.e. cancer, and other diseases using profiles of the ubiquitin-proteasome system determined from acellular body fluids or cell-containing samples. Further provided are methods of predicting response to therapy in certain populations of cancer patients.